Incytevs.Neurocrine Biosciences
INCY vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte is about 1.3× larger than Neurocrine Biosciences by market cap; Incyte trades at the lower P/E (16.1 vs 26.4); year to date, Neurocrine Biosciences leads (+24.9% vs +18.2%).
Side by side
| INCY | NBIX | |
|---|---|---|
| Market cap | $23.1B | $17.7B |
| Price | $116.71 | $177.11 |
| Today | −1.5% | −1.9% |
| Return YTD | +18.2% | +24.9% |
| Return 1Y | +65.9% | +31.3% |
| P/E | 16.1 | 26.4 |
| P/S | 4.3 | 5.7 |
| P/B | 4.1 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where INCY and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →